N-gene Research Laboratories, Inc.

Pecsi Tudomanyegyetem

Pésci Tudományegyetem

N-gene Research Laboratiories Inc.

Balázs Sümegi

Kalman Takacs

Peter Literati Nagy

Gábor Balogh

Péter Literáti Nagy

László Vígh

Zoltán Szilvássy

Kálmán Tory

Sándor Bernáth

Jesse Roth

József Mandl

János Egri

Attila Kolonics

László Vigh

Kálmán Hideg

Tamás Kálai

Zita Bognár

Ferenc Gallyas, Jr

Kálmán Tóth

Kálmán Takács

Sámuel Komoly

Ferenc Ifj Gallyas

Péter ÁCs

Zsolt ILLÉS

Sára VetÖ

Mike Brownstein

Zoltán Szilvassy

Sándor Bernath

Kálmán Takacs

Péter Literati Nagy

The invention relates to a compound selected from the group consisting of desethylamiodarone and pharmaceutically acceptable salts, hydrates and solvates thereof, as well as pharmaceutical composition comprising the compound together with a pharmaceutically acceptable excipient, vehicle or carrier, for use in the treatment of cancer.

Desethylamiodarone for use in cancer treatment

The subject of the present invention are quinazoline derivatives and their pharmaceutically acceptable salts of general formula (I), that inhibit a DNA-repairing enzyme, poly(ADP-ribose) polymerase (PARP), enabling them to be used for the preparation of pharmaceutical compositions for preventing or treating illnesses where PARP-inhibition yields a beneficial effect. In general formula (I) Rstands for either hydrogen or a group of general formula (a); Rstands for a) hydrogen or Calkyl group, if Ris other than hydrogen, and b) if Ris hydrogen, then Rmay be a group of general formula (b), (c) or (d). The subject of the present invention also embraces the preparation processes of the compounds described above.

Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having PARP enzyme inhibitory effect

O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime (BGP-15) or a pharmaceutically suitable acid addition salt thereof can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight gain.

Prevention and treatment of obesity

The invention refers to novel propenecarboxylic acid amidoxime derivatives furthermore N-oxides and/or geometrical isomers and/or optical isomers and/or pharmaceutically suitable acid addition salts and/or quaternary derivatives thereof. The novel compounds are suitable for the treatment of a state connected with oxygen deficit and/or energy deficit, or a disease based on PARP inhibition, especially an autoimmune or neurodegenerative disease, and/or a viral disease, and/or a disease caused by a toxic effect.

Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same

Pharmaceutical compositions that exhibit reduced gastrointestinal side-effects comprising a known active substance having antitumor effects selected from the group consisting of pyrimidine derivatives, or a pharmaceutically acceptable acid addition salt thereof, and O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime, or a pharmaceutically acceptable acid addition salt thereof, are disclosed.

Pharmaceutical composition that exhibits reduced side-effects comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime and a pyrimidine derivative with known antitumor activity

The invention refers to pharmaceutical compositions which have an enhanced antitumor activity or reduced side effect(s) comprising a known active substance having antitumor effect or a pharmaceutically acceptable salt thereof and a hydroximic acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.

Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxlmic acid derivative

Growing community of inventors

Pécs, Hungary

Balázs Sümegi